DelveInsight’s “Progressive Multifocal Leukoencephalopathy Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Progressive Multifocal Leukoencephalopathy, historical and forecasted epidemiology, as well as the Progressive Multifocal Leukoencephalopathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The Progressive Multifocal Leukoencephalopathy Market is an evolving segment of the global healthcare landscape, driven by the increasing Progressive Multifocal Leukoencephalopathy prevalence of the disorder and the continuous development of innovative treatment options. The Progressive Multifocal Leukoencephalopathy Market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.
Discover Key Insights into the Progressive Multifocal Leukoencephalopathy Market with DelveInsight's In-Depth Report @ Progressive Multifocal Leukoencephalopathy Market Size
Key Takeaways from the Progressive Multifocal Leukoencephalopathy Market Report
- In October 2024:- National Institute of Neurological Disorders and Stroke (NINDS)- A Pilot Study of NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy. Participants will have magnetic resonance imaging (MRI) of the brain. The MRI scanner is a metal cylinder surrounded by a magnetic field. During MRIs, participants will lie on a table that slides in and out of the scanner. Soft padding or a coil will be placed around their head. They will get gadolinium, a contrast agent, through an IV catheter.
- According to DelveInsight’s epidemiology model, in the US, the total incident cases of PML were approximately 1,687 in 2023. This number is anticipated to rise during the forecast period (2024-2034), driven by improved diagnostic techniques, along with the aging population.
- Among EU4 and the UK, Germany accounted for the highest number of incident cases of PML, with approximately 420 cases in 2023, followed by France with approximately 342 cases, and the UK with nearly 339 cases.
- Among the age-specific incident cases of PML in the US in 2023, the highest cases were observed in the 61–70 years age group with approximately 439 cases whereas the lowest cases were for the 20–30 years of age group with nearly 118 cases.
- In 2023, Japan accounted for approximately 617 incident cases of PML among the 7MM. These cases are expected to change during the forecast period.
- In 2023, the etiology-specific categories included hematological malignancies, HIV infection, chemotherapy medications, and autoimmune medications. Notably, HIV infection had the highest number of incident cases, with approximately 352 cases reported in Japan.
- The leading Progressive Multifocal Leukoencephalopathy Companies such as NeoImmuneTech, Inhibikase Therapeutics, Neurimmune, and others
- Promising Progressive Multifocal Leukoencephalopathy Therapies such as NT-I7, CE-VST01-JC, Natalizumab, and others.
Stay ahead in the Progressive Multifocal Leukoencephalopathy Therapeutics Market with DelveInsight’s Strategic Report @ Progressive Multifocal Leukoencephalopathy Market Outlook
Progressive Multifocal Leukoencephalopathy Epidemiology Segmentation in the 7MM
- Total Progressive Multifocal Leukoencephalopathy incident cases
- Progressive Multifocal Leukoencephalopathy age-specific incident cases
- Progressive Multifocal Leukoencephalopathy etiology-specific incident cases
Download the report to understand which factors are driving Progressive Multifocal Leukoencephalopathy epidemiology trends @ Progressive Multifocal Leukoencephalopathy Prevalence
Progressive Multifocal Leukoencephalopathy Emerging Drugs
- NT-I7 Monotherapy (efineptakin alfa): NeoImmuneTech
NT-I7 (efineptakin alfa) represents a significant advancement as the only clinical-stage long-acting human IL-7, targeting oncologic and immunologic applications by enhancing T cell amplification and functionality. IL-7 plays a critical role in the development of naïve and memory T cells and in sustaining immune responses against chronic and foreign antigens. Preliminary clinical trials demonstrate NT-I7’s favorable pharmacokinetic/pharmacodynamic (PK/PD) and safety profiles, both as a standalone treatment and in combination with other anticancer therapies. The drug is currently being evaluated in multiple studies for solid tumors and as a vaccine adjuvant, with plans for additional trials in hematologic malignancies and other immunological indications. Notably, in February 2021, the US FDA cleared an investigational new drug (IND) application for a pilot study assessing NT-I7 in PML, for which it received an Orphan Drug Designation in June 2020.
Progressive Multifocal Leukoencephalopathy Treatment Market Landscape
The Progressive Multifocal Leukoencephalopathy treatment landscape primarily includes antiviral agents, immunomodulators, and monoclonal antibodies. Antiviral therapies, such as cidofovir and mefloquine, target the underlying JC virus responsible for PML, though their efficacy remains limited. Immunomodulators, like natalizumab, are pivotal in PML management as they address the immune dysregulation seen in affected patients; however, their use can paradoxically increase PML risk. Additionally, monoclonal antibodies such as rituximab are under investigation for their potential to reconstitute the immune response against opportunistic infections. Collectively, these drug classes highlight the complexity of Progressive Multifocal Leukoencephalopathy treatment, necessitating a nuanced approach that balances antiviral efficacy with immune restoration.
Get In-Depth Knowledge on Progressive Multifocal Leukoencephalopathy Market Trends and Forecasts with DelveInsight @ Progressive Multifocal Leukoencephalopathy Treatment Market
Progressive Multifocal Leukoencephalopathy Market Outlook
The management of PML currently emphasizes immune restoration to improve survival rates, with antiretroviral therapy and addressing sources of immunosuppression as pivotal components. Despite several agents, including cytosine arabinoside, cidofovir, and mefloquine, being utilized, their effectiveness remains unproven in robust clinical trials. Notably, cytarabine has failed to demonstrate a significant impact on disease progression in randomized studies, while cidofovir has shown mixed results across different patient populations, with survival more closely linked to immune parameters than specific treatments. The emergence of novel therapies, such as NeoImmuneTech's NT-I7 (efineptakin alfa), highlights a potential shift towards leveraging immune-enhancing strategies. However, the overall pipeline for PML treatments appears underdeveloped, primarily comprising early-phase assets, indicating an urgent need for innovative therapeutic solutions to improve patient outcomes. The prognosis for most PML patients remains grim, underscoring the critical gap in effective treatment options.
Progressive Multifocal Leukoencephalopathy Drugs Market
The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment. The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Unlock Strategic Insights with DelveInsight’s Comprehensive Progressive Multifocal Leukoencephalopathy Market Report @ Progressive Multifocal Leukoencephalopathy Market Drivers and Barriers
Scope of the Progressive Multifocal Leukoencephalopathy Market Report
- Coverage- 7MM
- Progressive Multifocal Leukoencephalopathy Companies- NeoImmuneTech, Inhibikase Therapeutics, Neurimmune, and others
- Progressive Multifocal Leukoencephalopathy Therapies- NT-I7, CE-VST01-JC, Natalizumab, and others.
- Progressive Multifocal Leukoencephalopathy Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Progressive Multifocal Leukoencephalopathy Unmet Needs, KOL’s views, Analyst’s views, Progressive Multifocal Leukoencephalopathy Market Access and Reimbursement
Table of Content
1 Key Insights
2 Report Introduction
3 Market Overview at a Glance
4 Epidemiology and Market Methodology
5 Executive Summary
6 Key Events
7 Disease Background and Overview
8 Patient Journey
9 Epidemiology and Patient Population
10 The US
11 Emerging Therapies
12 Progressive Multifocal Leukoencephalopathy: 7 Major Market Analysis
13 SWOT Analysis
14 Unmet Needs
15 Market Access and Reimbursement
16 Appendix
17 DelveInsight Capabilities
18 Disclaimer
19 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
